"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
Paresthesias (including burning, tingling, stinging) and/or pruritus, usually manifested in the perineal region are frequently experienced upon injection of the initial dose of LUSEDRA (fospropofol disodium injection) . Inform the patient that these sensations are typically mild to moderate in intensity, last a short time, and require no treatment.
Requirement for a patient escort should be considered. The decision as to when patients who have received LUSEDRA (fospropofol disodium injection) , particularly on an outpatient basis, may again engage in activities requiring complete mental alertness, coordination and/or physical dexterity (e.g., operate hazardous machinery, sign legal documents, or drive a motor vehicle) must be individualized.
Last reviewed on RxList: 2/10/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Lusedra Information
- Lusedra Drug Interactions Center: fospropofol iv
- Lusedra Side Effects Center
- Lusedra FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Chronic Pain/Back Pain
Find tips and advances in treatment.